Lebrikizumab for eczema

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Sep 2022: Trial registered, NCT05559359
  2. 18 Oct 2022: Trial started, NCT05559359

The trials

NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

State
Under way
Phase
Phase 3
People
377 taking part
Started
18 Oct 2022
Primary completion
14 Jan 2026
Arms
Lebrikizumab (Cohort 1), Lebrikizumab (Cohort 2)
Results
None posted
  1. 29 Sep 2022: Trial registered
  2. 18 Oct 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.